Optovue motion-correction technology improves retinal OCT image quality
Optovue announced DualTrac Motion Correction technology for its retinal OCT AngioVue Imaging System.
IMAGE: The AngioVue retinal OCT scanner benefits from motion-correction technology. (Image credit: Optovue)
Optical coherence tomography (OCT) and OCT angiography (OCTA) systems developer Optovue (Fremont, CA) announced its DualTrac [trademarked] Motion Correction technology for its AngioVue Imaging System. DualTrac Motion Correction is a two-level approach to correcting motion artifacts on patients who have difficulty focusing on a central visual point during an eye exam, which is essential for high-quality OCTA imaging.
According to David Sarraf, clinical professor of ophthalmology at the Jules Stein Eye Institute, UCLA, and his colleagues, DualTrac Motion Correction on the AngioVue system has improved the quality of retinal images in most patients by correcting for naturally occurring motion artifacts that result from blinking and involuntary eye movements called saccades.
"In my opinion, and based on my experience before and after installing the new tracking technology, the scans produce higher quality images, especially in patients with blinking that is not severe," said Dr. Sarraf. "Additionally, we have observed less motion artifact with small eye saccades. The DualTrac system allows patients to blink during image scanning and prevents multiple repeat scans, thereby facilitating the overall acquisition process in most patients."
Optovue says it is the first company to develop and commercialize the pioneering OCTA technology. Using light rays to form detailed three-dimensional (3D) images of the retina, physicians are able to quickly visualize the blood flow in the retina. The AngioVue System produces a single image, derived from OCT data, that complements fluorescein angiography (FA), but with a number of advantages. Unlike FA, the AngioVue System does not require the use of dye injections, and can be accomplished in a matter of seconds.
"We are excited to bring to market groundbreaking technologies that provide valuable new, detailed information about the microvasculature of the eye, in a manner that reduces the burden for both the patient and the clinic staff," said Jay Wei, CEO for Optovue. "DualTrac Motion Correction allows for improved imaging and quicker data collection to further the clinical utility of OCTA technology by accommodating natural eye movement."